

# C - Index

## In this guide

### [In this guide](#)

1. [A - Index](#)
2. [B - Index](#)
3. [C - Index](#)
4. [D - Index](#)
5. [E - Index](#)
6. [F - Index](#)
7. [G - Index](#)
8. [H - Index](#)
9. [I - Index](#)
10. [J - Index](#)
11. [K - Index](#)
12. [L - Index](#)
13. [M - Index](#)
14. [N - Index](#)
15. [O - Index](#)
16. [P - Index](#)
17. [Q - Index](#)
18. [R - Index](#)
19. [S - Index](#)
20. [T - Index](#)
21. [U - Index](#)
22. [V - Index](#)
23. [W - Index](#)
24. [X - Index](#)
25. [Y - Index](#)
26. [Z - Index](#)

**Subject :****Cadmium,****Year Page**

in the 2006 Total Diet Study in the infant diet	2009 12
establishing a revised Tolerable Weekly Intake (TWI)	2009 12
Comparing exposure to the TWI established in 2009	2018 9
ongoing work on the COT contribution to the SACN risk assessment on nutrition and, cadmium	2021 31

**Subject:****Caffeine****Year Page**

Caffeine and alcohol: combined effects on health and behaviour	2012 7
EFSA consultation on a draft scientific opinion on the safety of caffeine	2015 7
Reproductive effects of	2001 22
Reproductive effects of	2007 24
Reproductive effects of	2008 14, 49

**Subject:****Calcium-parathyroid hormone axis****Year Page**

Phosphate and the, 2004 11, 54

**Subject:**

**Cancer**

**Year Page**

Oesophageal cancer 2004 178

The role of miRNA related effects and chemicals on cancer 2011 56

**Subject:**

**Cancer aetiology**

**Year Page**

and causal inference. 2017 53

**Subject:**

**Cancer incidence near municipal solid waste**

**Year Page**

**incinerators**

in Great Britain 2000 104

Update review of epidemiological studies on 2008 284

Review of 2009 240

**Subject:****Cancer risk****Year Page**

DNA adducts as a biomarker for 2008 277

Joint COC/COM symposium on genetic susceptibility to cancer 1998 35

Epidemiological data linking cancer and alcohol 1995 58

Modification of, COC discussion of 2021 76

**Subject:****Cannabidiol (CBD)****Year Page**

Cosmetic products, potential risks from use of topically applied CBD-containing 2020 28

COT review of, 2019 16,  
36

Genotoxicity of, COM evaluation 2020 50

Inhalation, potential adverse effects associated with exposure to CBD) by 2020 28

Position paper on CBD in food products 2020 11

Updated position paper on 2021 24

**Subject:**

**Canned foods** **Year Page**

Bisphenol A in 2001 8

**Subject:**

**Captan (fungicide)** **Year Page**

COM and COC Evaluation of 1993 35, 50

**Subject:**

**Caramel (Type 1)** **Year Page**

Evaluation of 1991 30

**Subject:**

**Carbaryl** **Year Page**

COM and COC Evaluation of 1995 30, 64

**Subject:**

**Carbon nanotubes** **Year Page**

Carcinogenicity of 2010 60

Carcinogenicity of 2011 58

**Subject:**

	<b>Year</b>	<b>Page</b>
<b>Carcinogenesis</b>		

age-related differences in susceptibility to	2006	281
--	------	-----

mode of action / human relevance framework	2005	134
--	------	-----

mode of action / human Relevance Framework	2008	279
--	------	-----

“Tissue Organisation Field Theory” of	2006	286
---------------------------------------	------	-----

Carcinogenic air pollutants, Quantification of risk	2002	128
---	------	-----

Carcinogenicity guidelines	1991	44
----------------------------	------	----

**Subject:**

	<b>Year</b>	<b>Page</b>
<b>Carcinogens</b>		

COC guidance on a strategy for the risk assessment of	2004	188
---	------	-----

Assessing the risks of acute or short-term exposure to	2007	179
--	------	-----

Early life exposure- assessing susceptibility from EPA risk assessment guideline: supplemental data for	2003	195
---	------	-----

Guidance Statements on the risk assessment of	2010	63
---	------	----

Occupational, HSE priority programme	2004	177
--------------------------------------	------	-----

Insulin-like growth factor-1 (IGF-1) in the diet, The potential carcinogenic risk of	2009 78
Interaction between genotype and chemicals in the environment on the induction of cancer in risk assessment	2011 53
Risk assessment of carcinogens, Revised guidance	2003 197
COC guidance on a strategy for the risk assessment of carcinogens	2004 188
Single or short term exposure to carcinogens	2005 140
Use of target organ mutagenicity data in carcinogen risk assessment	2005 124
Organ mutagenicity data in carcinogen risk assessment	2005 124

## **Subject:**

## **Carcinogenicity**

**Year Page**

Chemical carcinogenicity revisited	2019 50
Testing for carcinogenicity of pharmaceuticals	1997 112
Joint COM/COC on the significance of low level exposures to DNA adduct inducing chemicals	1996 48
‘Risk assessment methodologies and approaches for mutagenic and carcinogenic substances’, Preliminary Report by the EU Scientific Committees on Consumer Products, on Health and Environmental Risks, and on Emerging and Newly-Identified Risks on	2008 280

**Subject:****Carcinogenicity studies****Year Page**

in rats, Minimum duration of	2001 121
in rats, Minimum duration of	2002 130
OECD Guidance document for the performance of chronic toxicity and	2009 225
Revision of OECD Test Guidelines for	2008 282
tobacco products, testing of	2009 219
Longevity of carcinogenicity studies: consideration of a database prepared by the Pesticides Safety Directorate	2000 109
Nephropathy observed in a 2-year carcinogenicity study	2008 12
T25 to estimate carcinogenic potency	1995 72
Validation of short-term carcinogenicity tests using transgenic animals, Presentation on	1999 73

**Subject:****Carrageenan****Year Page**

Allergic food intolerance, COT evaluation of	1997 11
Immune system, possible effects due to uptake by the gut-associated lymphoid tissues.	1993 12



Infant formulae, COT evaluation of use in	1991 14
---	---------

**Subject:**

## **Cell lines expressing human xenobiotic metabolising enzyme in mutagenicity testing**

**Year Page**

COM review of	1995 38
---------------	---------

**Subject:**

## **Cell transformation assays**

**Year Page**

COM review of	1994 26
---------------	---------

COM review of	2012 44
---------------	---------

For the prediction of carcinogens	2012 37
-----------------------------------	---------

**Subject:**

## **Chemical risk assessment**

**Year Page**

Evolving approaches to,	2007 23, 38
-------------------------	----------------

Interaction between genotype and chemicals in the environment on the induction of cancer in risk assessment	2011 53
---	---------

**Subject:****Year Page****Childhood cancer**

Age as an independent risk factor for chemically induced acute myelogenous leukaemia in children 2008 276

Childhood leukaemia and residence near sources of traffic exhaust and petrol fumes: review of the possible associations between 2005 143

Hazard proximities in Great Britain (from 1953 to 1980) 1997 110

Ongoing COC review of 2004 191

Ongoing COC review of 2005 134

Paternal smoking and 1997 68

**Subject:****Year Page****Children**

Research project (T07040) investigating the effect of mixtures on certain food colours and a preservative on behaviour in 2007 8, 49

Children's Environment and Health Strategy for the UK 2008 9

**Subject:****Year Page****Chlordecone**

Endosulfan, pentachlorobenzene and in the infant diet 2013 18

**Subject:**

**Chlorinated and brominated  
contaminants**

**Year Page**

in shellfish, farmed and wild fish

2006 10,  
67

**Subject:**

**Chlorinated drinking water**

**Year Page**

Mutagenic activity of

1991 32

Epidemiology and cancer

1992 55

**and cancer**

**Year Page**

Chlorinated drinking water

2007 185

Chlorinated drinking water

2008 278,  
285

**and reproductive outcomes**

**Year Page**

Chlorinated Drinking Water and

1998 8

Chlorinated drinking water and

2001 18

Chlorinated drinking water

2004 8, 46

Chlorinated paraffins in food	2009 13, 111
-------------------------------	--------------

Chlorination disinfection by-products and risk of congenital anomalies in England and Wales – new SAHSU study	2008 9
--	--------

**Subject:**

<b>Chlorine and chlorine dioxide as flour treatment agents</b>	<b>Year Page</b>
--	------------------

COM review of	1993 33
---------------	---------

COT and COM review of	1996 7, 36
-----------------------	------------

**Subject:**

<b>Chlorobenzenes</b>	<b>Year Page</b>
-----------------------	------------------

COT review of	1997 12
---------------	---------

<b>2-Chlorobenzylidene malonitrile (CS)</b>	<b>Year Page</b>
---	------------------

COT review of	1998 32
---------------	---------

new formulation of, and PAVA (Nonivamide) sprays: combined use and CS Spray

new formulation of PAVA (Nonivamide) and CS Spray respectively	2017 28
--	---------

Ongoing work, co-exposure	2005 17
---------------------------	---------

co-exposure 2006 7, 21

Review of CS Spray as a chemical incapacitant in relation to potential public health concerns 1999 7, 51

Combined use of CS (2-chloro-benzylidene malonitrile) and PAVA (nonivamide) (captor 2) irritant sprays 2013 14

**Subject:**

## **Chlorodibromomethane and chloroform**

**Year Page**

See trihalomethanes in drinking water 1994 22, 23, 32

**Subject:**

**Year Page**

## **Chlorophenols**

COM review of genotoxicity 2011 45

genotoxicity of 2012 37

**Subject:**

**Year Page**

## **Cholangiocarcinoma**

Evidence for an increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1996 2000 107

in the rat 2005 155

**Subject:****Year Page****Chromium picolinate**

COM ongoing review of

2003 141

COM review of the available information on the mutagenicity of trivalent chromium and specifically on chromium picolinate

2004 135,  
148

**Subject:****Year Page****Chromium VI**

COM review of

2015 36

**Subject:****Year Page****Chrysotile-substitutes,**

Carcinogenic risks

1998 50

**Subject:****Year Page****Chymosin (enzyme)**

from genetically modified Escherichia coli K12 in cheese manufacture

1991 16,  
28

Enzyme submission to COT

2000 16

Enzyme submission; chymosin preparation derived from GM aspergillus niger var. awamori

2002 10

**Subject:**

**Climate change**

	<b>Year</b>	<b>Page</b>
COC evaluation of	2011	52

**Subject:**

**COC guidance**

	<b>Year</b>	<b>Page</b>
Review of	2001	142
Revision of	2002	134
COC template	2002	129
COM template	2002	87
on a strategy for the risk assessment of carcinogens	2004	188

**Subject:**

**COM guidance**

	<b>Year</b>	<b>Page</b>
On ICH guidelines: Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals (S2B) and consideration of the mouse lymphoma assay	1997	75
Joint COM/COC on the significance of low level exposures to DNA adduct inducing chemicals	1996	48

Joint symposium with COM on use of target organ mutagenicity in carcinogen risk assessment	2004 192
--	----------

Joint meeting of COT/COM on use of target organ mutagenicity assays in carcinogen risk assessment	2005 92, 124
---	--------------

**Subject:**

**Year Page**

**CONCAWE**

Assessment of exposure to petrol vapour	2005 145
---	----------

Assessment of exposure to benzene vapour	2005 146
--	----------

**Subject:**

**Year Page**

**Comet Assay**

in mutagenicity testing strategies	1998 35
------------------------------------	---------

published literature on the use of this assay to detect chemical mutagens	1995 39
---	---------

Statement on joint COC and COM meeting 9 June 2005	2005 125
--	----------

Statement on a comparison of the relative performance of the in vivo rat liver UDS assay and the in vivo Comet assay	2006 249
--	----------

**Subject:**

**Year Page**

**Comfrey**



Report, pyrrolizidine alkaloid (PA), in vivo data 1992 19

results of a survey of comfrey 1994 7

**Subject:**

	<b>Year</b>	<b>Page</b>
<b>Committee procedures</b>		
Code of Conduct for Observers	2007	18
Code of practice, revision of COT	2020	21
Code of Practice for Scientific Advisory Committees CoPSAC) second round of consultation	2001	106
Code of Practice for Scientific Advisory Committees, the updating of.	2007	18
Consultation document for updating the Code of Practice for Scientific Advisory Committees	2010	23
EFSA consultation on draft guidance on biological relevance	2017	17
EFSA consultation on draft guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age	2017	19
EFSA consultation on draft guidance on weight of evidence	2017	18
EFSA opinion on statistical significance and biological relevance	2011	22

Draft EFSA protocol for a systematic review on health outcomes related to the age of introduction of complementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet	2017	20
EFSA consultation on draft EFSA/ECHA guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009	2018	17
EFSA consultation on draft guidance on risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain: Part 1, human and animal health	2018	18
EFSA consultation on draft guidance on threshold of toxicological concern approach	2018	20
EFSA public consultation on draft Scientific Opinion on evaluation of the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels	2018	20
Public consultation on the EFSA Opinion on "Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food."	2018	20
EFSA public consultation on the MIXTOX guidance	2018	21
EFSA safety assessment of certain flavouring substances, COM consideration	2018	42
EFSA consultation on genotoxicity of mixtures	2018	42
EFSA consultation on phthalates	2019	14

EFSA consultation on the EFSA opinion on risk to public health related to the presence of ochratoxin in food.	2020	22
EFSA Public consultation on the EFSA draft Opinion “Risk to human health related to the presence of perfluoroalkyl substances in food	2020	23
EFSA consultation on the EFSA opinion on risks for animals and human health related to the presence of glycoalkaloids in feed and food, in particular in potatoes and potato-derived products	2020	24
EFSA Public consultation on the EFSA draft “Update of the risk assessment of nickel in food and drinking water”	2020	25
EFSA consultation on the EFSA opinion on the update of the risk assessment of hexabromocyclododecanes (HBCDDs) in food	2020	26
EFSA recommendations on Default values to be used in risk assessment in the absence of actual measured data	2012	7
Review of the 2018 EFSA opinion on dioxins	2021	18
Review of the 2021EFSA opinion on titanium dioxide	2021	23
Draft EFSA Scientific Committee Opinion on scientific criteria for grouping chemicals into assessment groups for human risk assessment of combined exposure to multiple chemicals	2021	26
Draft EFSA Scientific Committee Opinion on biological plausibility of non-monotonic dose responses and their impact on the risk assessment	2021	27

EFSA draft opinion on “Identification and prioritisation for risk assessments of phthalates, structurally similar substances potentially used as plasticisers in materials and articles intended to come into contact with food” and “draft protocol for the exposure assessment as part of the safety assessment of phthalates, structurally similar substances potentially used as plasticisers in materials and articles intended to come into contact with food”	2021	28	
Food Standards Agency review of scientific committees	2001	24	
Good Practice Agreement for Scientific Advisory Committees	2006	16	
Public Consultation on Code of Practice for Scientific Advisory Committees and Councils	,2021	29	
Horizon Scanning: Multiple emerging or developing topics of importance within the COT / COM / COC remit.	Every year	Consult individual report	
In the light of the Phillips enquiry (COC)	2001	9, 106	
Open Meetings – review of procedure	2006	17	
Peer review by EU-ANSA agencies	2017	20	
Performance evaluation for Committee members	2006	17	
Procedure for holding COT meetings in open session	2003	18	
Quinquennial Review of the COT	2011	23	
Reviews of risk procedures used by Government advisory Committees dealing with food (COM)	2000	22, 110	

Second round of consultation	2003 12, 106
Uncertainty framework from a social science perspective	2011 25
WHO public consultation on the JECFA/JMPR update of Chapter 5 (EHC 240)	2020 26, 51

## **Subject:**

	<b>Year Page</b>
<b>Committee workshops</b>	
Bystander Risk Assessment Working Group (BRAWG)	2011 26
Diet and drug interaction	2005 7
ECETOC workshop on use of T25 in chemical carcinogen evaluation	2001 141
Epigenetics in carcinogenesis	2016 42
Epigenetics, transgenerational	2008 19, 36
Exploring Dose- response	2020 21
Genotoxicity data, interpretation of	2020 48
ILSI/HESI workshop on less-than-lifetime exposure to carcinogens	2012 44
International workshop on the categorisation of mutagens	2001 108
PBPK for regulators	2020 22
Social Science insights for risk assessment	2006 17

**Subject:**

<b>Contaminants in the diet of infants and young children</b>	<b>Year</b>	<b>Page</b>
---	-------------	-------------

Overarching statement.	2019	8
------------------------	------	---

possible health risks from the exposure of infants to HBCDDs in breast milk, dust and food	2014	12
--	------	----

contaminants in- overarching statement.	2019	8
---	------	---

**Subject:**

<b>Contaminants in soil</b>	<b>Year</b>	<b>Page</b>
-----------------------------	-------------	-------------

assessing the possible risks to human health associated with exposure to	2001	10
--	------	----

Updated framework guidance, establishing a TDI	2008	9
--	------	---

new screening levels	2013	15, 54
----------------------	------	-----------

**Subject:**

<b>Copper</b>	<b>Year</b>	<b>Page</b>
---------------	-------------	-------------

in the infant diet	2018	10
--------------------	------	----

**Subject:**

**Coumarin** **Year Page**

And liver cancer, COT review of 1998 29, 41

**Subject:**

**CRISPR gene editing technology-** **Year Page**

potential for genotoxicity 2018 41

**Subject:**

**CS Sabre 540010-01,** **Year Page**

new formulation 2018 16

**Subject:**

**Cyanogenic glycosides** **Year Page**

in apricot kernels 2006 7, 29

EFSA public consultation on draft Scientific Opinion on evaluation of the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels 2018 20

**Subject:**

**Cyclamate** **Year Page**

COT review of 1995 6

**Subject:**

**Cycloastragenol** **Year Page**

COC evaluation of 2015 42